PREDICT (2023 - 2026)

Ciliopathies are genetically and phenotypically heterogenous disorders and this inherent heterogeneity often hinders timely and precise diagnosis, which is essential to the patients and their families. As the leader of WP3, the MBC group will develop robust cellular and molecular cilium and centriolar satellite phenotyping assays that can functionally evaluate and/or validate genetic ciliopathy diagnoses, and classify patients based on their cilium phenotype. Learn more about PREDICT project here.